Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

Firmagon® has a proven safety profile of over 5 years

ADVERSE EVENT RATES WITH FIRMAGON VS LEUPROLIDE

ADVERSE EVENT RATES
WITH FIRMAGON VS LEUPROLIDE
FIRMAGON 240/80 mg
(subcutaneous) N=207
leuprolide 7.5 mg
(intramuscular) N=201
Percentage of subjects with adverse events79%78%
Body as a whole
Injection site adverse events35%/4%*<1%
Weight increase9%12%
Fatigue3%6%
Chills5%0%
Cardiovascular system
Hot flash26%21%
Hypertension6%4%
Musculoskeletal system
Back pain6%8%
Arthralgia5%9%
Urogenital system
Urinary tract infection5%9%
Digestive system
Increases in transaminases and GGT10%5%
Constipation5%5%

FIRMAGON

240/80 mg

(subcutaneous)

N = 207

leuprolide

7.5 mg

(intramuscular)


N = 201

Percentage of subjects with adverse events
79%
78%
Body as a whole Injection site adverse events
35%*
<1%
Body as a wholeWeight increase
9%
12%
Body as a wholeFatigue
3%
6%
Body as a wholeChills
5%
0%
Cardiovascular systemHot Flash
26%
21%
Cardiovascular systemHypertension
6%
4%
Musculoskeletal systemBack pain
6%
8%
Musculoskeletal systemArthralgia
5%
9%
Urogenital systemUrinary track infection
5%
9%
Digestive systemIncreases in transaminases and GGT
10%
5%
Digestive system Constipation
5%
5%

The most common adverse reactions reported in ≥10% of the patients were injection site reactions (eg, pain, erythema, swelling, induration, or inflammation), pyrexia, hot flush, weight loss or gain, fatigue, and increases in serum levels of hepatic transaminases and gamma-glutamyltransferase (GGT).

In the pivotal trial, <1% of patients (n=7) in the pooled FIRMAGON group, compared to 2% of patients (n=4) in the leuprolide group, had a QTcF ≥500 msec. From baseline to end of study, the median change for FIRMAGON was 12.3 msec and 16.7 msec for leuprolide.1

*Injection site reactions occurred in only 4% of maintenance dose injections.2

Patients have safely switched from leuprolide to FIRMAGON

In an extension study, 135 patients crossed over from leuprolide to FIRMAGON.

Abbreviations: ADT = androgen deprivation therapy; GGT = gamma-glutamyltransferase; QTcF = QT Interval Corrected by the Fridericia Correction Formula.

Monthly Matters

Help make the most of your patient's
treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.
Actual physician quote

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.